市場調查報告書

C型肝炎治療藥的全球市場 - 各藥物類別·各流通管道·各地區:市場規模·佔有率·未來展望·機會分析

Hepatitis C Drugs Market, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

出版商 Coherent Market Insights 商品編碼 924636
出版日期 內容資訊 英文 151 Pages
商品交期: 2-3個工作天內
價格
C型肝炎治療藥的全球市場 - 各藥物類別·各流通管道·各地區:市場規模·佔有率·未來展望·機會分析 Hepatitis C Drugs Market, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
出版日期: 2020年01月16日內容資訊: 英文 151 Pages
簡介

本報告提供全球C型肝炎的治療藥的市場相關分析,提供疾病概要,及市場基本結構及促進·阻礙因素,整體市場規模預測 (今後9年份),各藥物類別·各流通管道·各地區的詳細趨勢,主要企業的簡介·業績·策略計劃等調查。

第1章 分析目的·前提條件

第2章 市場概要

  • 分析概要
    • 市場定義和範圍
  • 摘要整理
  • COM (Coherent Opportunity Map:市場機會藍圖)

第3章 市場動態·規定·趨勢分析

  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 市場機會
  • 影響度分析
  • 市場趨勢
  • 近幾年主要的動向
  • 醫療費償付方案
  • 波特的五力分析
  • PEST分析

第4章 全球C型肝炎治療藥市場:各藥物類別 (以金額為準,2019∼2027年)

  • 簡介
  • 干擾素治療
  • NS5A抑制劑
  • NS5B抑制劑
  • 蛋白分解酵素抑制劑

第5章 全球C型肝炎治療藥市場:各流通管道 (以金額為準,2019∼2027年)

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第6章 全球C型肝炎治療藥市場:各地區 (以金額為準,2019∼2027年)

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 非洲
  • 中東

第7章 競爭環境

  • 公司概要
    • Abbvie Inc.
    • Gilead sciences, Inc.
    • BRISTOL-MYERS Squibb Company
    • F Hoffmann-la Roche Ltd
    • Merck & co., Inc.
    • Johnson & Johnson
    • Natco Pharma Limited
    • Kadmon holdings, Inc.
  • 分析師的見解

第8章 附錄

目錄

Hepatitis C virus is a blood-borne virus that infects liver cells, resulting in illness that ranges from mild and transient effects such as easy bleeding, fatigue, yellow discoloration of skin and eyes, and others to chronic and serious life-threatening conditions such as liver cirrhosis, liver cancer or liver failure. Hepatitis C virus is transmitted through needlestick injuries, organ transplant from a carrier, and sexually or from infected mother to fetus.

Globally, hepatitis C virus exists in six distinct forms based on its genotypes, amongst which Type 1 is the most common form representing around 60-70% of global infections. Hepatitis C is diagnosed by blood tests for estimating viral load and genotyping, and liver damage tests such as magnetic resonance elastography (MRE), transient elastography, and liver biopsy. Antiviral drugs, which inhibits protease or polymerase enzyme of virus is one of the treatments available for infection caused due to hepatitis C. Currently, no vaccines are available for the prevention of hepatitis C virus and this provides scope for the market players to expand their company portfolio.

Market Dynamics

Increasing prevalence of hepatitis C is expected to drive growth of hepatitis C drugs market over the forecast period. For instance, in 2018, according to the Centers for Disease Control and Prevention (CDC), around 3.9 million of U.S. population suffered from hepatitis C. Hepatitis C virus (HCV) infection is a commonly found blood borne infection in the U.S.

Moreover, in Canada, 246,000 number of Canada population suffered with HCV disease in 2017, wherein around 44% were unaware about HCV infection.

However, high cost of hepatitis C treatment is expected to hamper growth of the hepatitis C drugs market during the forecast period. For instance, in the U.S., a 12-week course of Sovaldi costs around US$ 84,000, where one pill costs around US$ 1,000. Similarly, Olysio drug costs around US$ 23,600 per month of hepatitis C treatment and treatment period for this drug was around 24-48 weeks.

Key features of the study:

  • This report provides in-depth analysis of the global hepatitis C drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%) for the forecast period, 2019-2027, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global hepatitis C drugs market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Abbvie Inc., Gilead sciences, Inc., BRISTOL-MYERS Squibb Company., F Hoffmann-la Roche Ltd, Merck & co., Inc., Johnson & Johnson, Natco Pharma Limited, and Kadmon holdings, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological upgradation, market expansion, and marketing tactics
  • The global hepatitis C drugs market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for global hepatitis C drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Hepatitis C drugs Market, by Drug Type:
    • Interferon Based Therapies
    • NS5A Inhibitors
    • NS5B Inhibitors
    • Protease Inhibitors
  • Global Hepatitis C drugs Market, by Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hepatitis C drugs Market, by Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug Type:
    • Interferon Based Therapies
    • NS5A Inhibitors
    • NS5B Inhibitors
    • Protease Inhibitors
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug Type:
    • Interferon Based Therapies
    • NS5A Inhibitors
    • NS5B Inhibitors
    • Protease Inhibitors
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug Type:
    • Interferon Based Therapies
    • NS5A Inhibitors
    • NS5B Inhibitors
    • Protease Inhibitors
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug Type:
    • Interferon Based Therapies
    • NS5A Inhibitors
    • NS5B Inhibitors
    • Protease Inhibitors
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug Type:
    • Interferon Based Therapies
    • NS5A Inhibitors
    • NS5B Inhibitors
    • Protease Inhibitors
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Drug Type:
    • Interferon Based Therapies
    • NS5A Inhibitors
    • NS5B Inhibitors
    • Protease Inhibitors
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Abbvie Inc *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Gilead sciences, Inc.
    • BRISTOL-MYERS Squibb Company.
    • F Hoffmann-la Roche Ltd
    • Merck & co., Inc.
    • Johnson & Johnson
    • Natco Pharma Limited
    • Kadmon holdings, Inc.
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Reimbursement scenario
  • Porter's Analysis
  • PEST Analysis

4. Global Hepatitis C Drugs Market, By Drug Type, 2019 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Interferon Based Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027 , (US$ Million)
  • NS5A Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027 , (US$ Million)
  • NS5B Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027 , (US$ Million)
  • Protease Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027 , (US$ Million)

5. Global Hepatitis C Drugs Market, By Distribution Channel, 2019 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027 , (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027 , (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027 , (US$ Million)

6. Global Hepatitis C Drugs Market, By Region, 2019 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Type, 2016 - 2027 , (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027 , (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027 , (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Type, 2016 - 2027 , (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027 , (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027 , (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2016 - 2027 , (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027 , (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027 , (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Type, 2016 - 2027 , (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027 , (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027 , (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Type, 2016 - 2027 , (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027 , (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027 , (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Type, 2016 - 2027 , (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027 , (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027 , (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East

7. Competitive Landscape

  • Company Profiles
    • Abbvie Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Gilead sciences, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • BRISTOL-MYERS Squibb Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • F Hoffmann-la Roche Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & co., Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Natco Pharma Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Kadmon holdings, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About Us and Sales Contact